Literature DB >> 21907117

High prevalence of amblyopia risk factors in preverbal children with nasolacrimal duct obstruction.

Noelle S Matta1, David I Silbert.   

Abstract

PURPOSE: To report the percentage of children under the age of 3 with nasolacrimal duct obstruction (NLDO) and amblyopia risk factors who develop clinical evidence of amblyopia over time.
METHODS: Records of children under 3 years of age presenting to a pediatric oculoplastic specialist with NLDO between January 1, 2001, and August 8, 2009, were retrospectively reviewed to identify those who also had amblyopia risk factors. Amblyopia was diagnosed based on visual acuity and treatment history.
RESULTS: A total of 375 children under the age of 3 had NLDO. Of these, 82 (22%) had amblyopia risk factors, and 70 received a follow-up examination. Average age at first visit was 12 months (1-27 months). In all patients with anisometropia and unilateral NLDO, the side with the NLDO had higher hyperopia. Of the 70 with risk factors, 44 (63%) were later treated for amblyopia: 29 with spectacles alone, 2 with occlusion therapy, 13 with spectacles and occlusion therapy. Six patients required strabismus surgery. In all patients with anisometropia and unilateral NLDO, the side with the NLDO had higher hyperopia.
CONCLUSIONS: The percentage of children identified with amblyopia risk factors who later develop clinical amblyopia was much higher than the 1.6% to 3.6% expected in a cohort of normal children.
Copyright © 2011 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21907117     DOI: 10.1016/j.jaapos.2011.05.007

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  9 in total

1.  [Treatment of congenital lacrimal duct obstruction: A prospective clinical cohort study].

Authors:  J Heichel; F Bachner; A Schmidt-Pokrzywniak; H-G Struck; U Stuhlträger; T Bredehorn-Mayr
Journal:  Ophthalmologe       Date:  2015-10       Impact factor: 1.059

Review 2.  [Congenital nasolacrimal duct obstruction from an ophthalmologist's point of view : Causes, diagnosis and staged therapeutic concept].

Authors:  J Heichel; T Bredehorn-Mayr; H-G Struck
Journal:  HNO       Date:  2016-06       Impact factor: 1.284

3.  The prevalence of amblyogenic factors in children with persistent congenital nasolacrimal duct obstruction.

Authors:  Bahram Eshraghi; Mohammad Reza Akbari; Masoud Aghsaei Fard; Azadeh Shahsanaei; Raheleh Assari; Arash Mirmohammadsadeghi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-29       Impact factor: 3.117

4.  Prevalence of amblyopia in children undergoing nasolacrimal duct irrigation and probing.

Authors:  Ozlen Rodop Ozgur; Isıl Bahar Sayman; Yesim Oral; Berkay Akmaz
Journal:  Indian J Ophthalmol       Date:  2013-12       Impact factor: 1.848

5.  Nasolacrimal duct obstruction: Does it really increase the risk of amblyopia in children?

Authors:  V Akila Ramkumar; Sumita Agarkar; Bipasha Mukherjee
Journal:  Indian J Ophthalmol       Date:  2016-07       Impact factor: 1.848

6.  Anisometropia and refractive status in children with unilateral congenital nasolacrimal duct obstruction.

Authors:  Adnan Aslam Saleem; Sorath Noorani Siddiqui; Umair Wakeel; Muhammad Asif
Journal:  Taiwan J Ophthalmol       Date:  2018 Jan-Mar

7.  Amblyopia risk factors in congenital nasolacrimal duct obstruction: A longitudinal case-control study.

Authors:  YungJu Yoo; Hee Kyung Yang; Namju Kim; Ho-Kyoung Choung; Jeong-Min Hwang; Sang-In Khwarg
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

8.  Prevalence and Risk Factors of Amblyopia among Refractive Errors in an Eastern European Population.

Authors:  Valeria Mocanu; Raluca Horhat
Journal:  Medicina (Kaunas)       Date:  2018-03-20       Impact factor: 2.430

Review 9.  Congenital Nasolacrimal Duct Obstruction (CNLDO): A Review.

Authors:  Aldo Vagge; Lorenzo Ferro Desideri; Paolo Nucci; Massimiliano Serafino; Giuseppe Giannaccare; Andrea Lembo; Carlo Enrico Traverso
Journal:  Diseases       Date:  2018-10-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.